Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME versus FETROJA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME versus FETROJA.
CEFUROXIME vs FETROJA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and leading to cell lysis.
Cefiderocol is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, and is stable against a broad range of beta-lactamases, including carbapenemases, due to its ability to penetrate the outer membrane via the bacterial iron transport system.
250-500 mg orally twice daily; 750 mg-1.5 g IV/IM every 8 hours for moderate infections; 1.5 g IV/IM every 8 hours for severe infections.
1 gram intravenously over 3 hours every 8 hours in patients 18 years and older with creatinine clearance ≥ 60 mL/min.
None Documented
None Documented
Clinical Note
moderateCefuroxime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefuroxime."
Clinical Note
moderateCefuroxime + Cimetidine
"Cefuroxime can cause a decrease in the absorption of Cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy."
Clinical Note
moderateCefuroxime + Methantheline
"Cefuroxime can cause a decrease in the absorption of Methantheline resulting in a reduced serum concentration and potentially a decrease in efficacy."
Clinical Note
moderateTerminal elimination half-life is 1.2 hours in adults with normal renal function (increased to 15-22 hours in severe renal impairment [CrCl <10 mL/min], requiring dose adjustment).
Terminal elimination half-life: 2.5-3.5 hours; prolonged in renal impairment (e.g., up to 5-6 hours in severe renal impairment), requiring dose adjustment
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (<10%).
Renal: approximately 65-70% of the dose excreted unchanged in urine; biliary/fecal: minimal (<1%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
Cefuroxime + Olanzapine
"Cefuroxime can cause a decrease in the absorption of Olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy."